BerGenBio Valuation

Is 7BG0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 7BG0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 7BG0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 7BG0's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 7BG0?

Other financial metrics that can be useful for relative valuation.

7BG0 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue366.1x
Enterprise Value/EBITDA-1.2x
PEG Ration/a

Price to Book Ratio vs Peers

How does 7BG0's PB Ratio compare to its peers?

The above table shows the PB ratio for 7BG0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.6x
MDG1 Medigene
1.6x-4.1%€31.0m
HPHA Heidelberg Pharma
2.7x-31.2%€112.8m
CNW co.don
1xn/a€6.5m
2INV 2invest
1xn/a€60.4m
7BG0 BerGenBio
2.2x-25.0%€390.9m

Price-To-Book vs Peers: 7BG0 is expensive based on its Price-To-Book Ratio (2.2x) compared to the peer average (1.8x).


Price to Earnings Ratio vs Industry

How does 7BG0's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a34.8%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a34.8%
n/an/an/a
No more companies

Price-To-Book vs Industry: 7BG0 is good value based on its Price-To-Book Ratio (2.2x) compared to the European Biotechs industry average (2.5x).


Price to Book Ratio vs Fair Ratio

What is 7BG0's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

7BG0 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 7BG0's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 7BG0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.80
€1.71
+114.2%
68.2%€3.25€0.43n/a3
Sep ’25€0.91
€1.71
+87.6%
68.2%€3.25€0.43n/a3
Aug ’25€1.10
€2.58
+134.6%
92.1%€5.89€0.42n/a3
Jul ’25€0.99
€2.91
+194.0%
81.5%€6.12€0.44n/a3
Jun ’25€1.08
€2.91
+169.0%
81.5%€6.12€0.44n/a3
May ’25€1.10
€6.59
+499.1%
114.2%€17.19€0.43n/a3
Apr ’25€1.51
€6.48
+329.2%
114.2%€16.91€0.42n/a3
Mar ’25€1.56
€6.48
+315.4%
114.2%€16.91€0.42n/a3
Feb ’25€2.19
€6.48
+195.9%
114.2%€16.91€0.42n/a3
Jan ’25€2.38
€6.48
+172.3%
114.2%€16.91€0.42n/a3
Dec ’24€1.21
€6.48
+435.6%
114.2%€16.91€0.42n/a3
Nov ’24€1.53
€49.37
+3,126.6%
116.8%€130.29€0.43n/a3
Oct ’24€0.81
€49.37
+5,994.7%
116.8%€130.29€0.43€0.813
Sep ’24€0.84
€49.37
+5,777.0%
116.8%€130.29€0.43€0.913
Aug ’24€0.77
€134.02
+17,305.1%
81.4%€267.74€0.45€1.103
Jul ’24€0.02
€130.75
+653,665.8%
77.2%€255.82€8.53€0.993
Jun ’24€1.42
€130.75
+9,108.0%
77.2%€255.82€8.53€1.083
May ’24€16.00
€130.75
+717.2%
77.2%€255.82€8.53€1.103
Apr ’24€40.94
€173.75
+324.4%
49.1%€289.58€86.87€1.513
Mar ’24€57.30
€173.75
+203.2%
49.1%€289.58€86.87€1.563
Feb ’24€62.45
€173.75
+178.2%
49.1%€289.58€86.87€2.193
Jan ’24€69.15
€173.75
+151.3%
49.1%€289.58€86.87€2.383
Dec ’23€87.70
€173.75
+98.1%
49.1%€289.58€86.87€1.213
Nov ’23€75.00
€119.07
+58.8%
25.0%€148.83€89.30€1.532
Oct ’23€56.05
€119.07
+112.4%
25.0%€148.83€89.30€0.812

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies